Intellia Therapeutics (NTLA) Misses Q3 EPS by 13c; Cash and Cash Equivalents of $1.15B

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/7/2026

1. SPCX
2. CRNX
3. VRTX
4. WMT
5. USO
6. SPY
7. RXST
8. RIVN
9. LMT
10. SPGI

Go back to Intellia Therapeutics (NTLA) Misses Q3 EPS by 13c; Cash and Cash Equivalents of $1.15B

Intellia Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress

November 4, 2021 7:30 AM EDT

Initiated dosing of Cohort 4 in the ongoing Phase 1 study of NTLA-2001; data update from completed dose-escalation (Part 1) and initiation of dose-expansion (Part 2) expected in Q1 2022Accelerated plans to evaluate NTLA-2001 for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) On track to initiate first-in-human studies of NTLA-2002 for hereditary angioedema (HAE) and NTLA-5001 for acute myeloid leukemia (AML) by year-end Announces nomination of NTLA-3001, its first gene insertion development candidate, for alpha-1 antitrypsin deficiency (AATD); concurrently, Regeneron and Intellia have selected a Factor 9 gene insertion development candidate to advance... More